企業プロフィール
Liquidia Corporation 株価・ニュース・カタリスト
- ティッカー:
- LQDA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
77.70 USD (+4.38%)
終値
最終更新: 2026年8月17日
4.9B USD
時価総額
株価変動の要因
As of Aug 17, 2026, LQDA closed up 4.38% at $77.70. No new same-company headline was identified in the current news window.
企業概要
Pulmonary Hypertension Company
Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines.
YUTREPIA
YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved in the United States for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
PRINT Technology
Liquidia's PRINT manufacturing platform produces particles with controlled size, shape, and composition. The company uses this capability to create inhaled formulations intended to simplify administration and support dose flexibility.
L606
L606 is a sustained-release inhaled formulation of treprostinil delivered twice daily with a next-generation nebulizer. The pivotal Re-Spire study is evaluating the program in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Clinical Expansion Strategy
Liquidia is conducting multiple studies across YUTREPIA and L606 to generate evidence in established indications and explore additional uses for inhaled treprostinil.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。